ScreenerHero

PLX Protalix BioTherapeutics, Inc.

AMEX · US · Healthcare · Biotechnology · protalix.com
2.710USD-0.73%Mkt Cap: 218.35M $P/E: 11.78

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression sy…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap218.35M USD
Enterprise Value188.51M USD
Revenue (TTM)80.62M USD
Gross Profit25.75M USD
Net Income (TTM)-6.60M USD
Revenue/Share1.01 USD
Last Price2.710 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees226
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)11.78
P/E (Forward)4.40
PEG—
EV/EBITDA7.58
EV/Revenue2.34
P/S2.73
P/B3.08
EPS (TTM)0.23
EPS (Forward)0.62
52W Range
1.60070% of range3.190
52W High3.190 USD
52W Low1.600 USD
Profitability
Gross Margin48.82%
Oper. Margin23.48%
EBITDA Margin30.84%
Profit Margin-12.52%
ROE-13.69%
ROA-8.02%
Growth
Revenue Growth27.10%
Earnings Growth2241.10%
Cash Flow & Leverage
Operating CF-11.99M USD
CapEx (TTM)1.64M USD
FCF Margin3.71%
FCF Yield1.37%
Net Debt-31.45M USD
Net Debt/EBITDA-1.27
Balance Sheet
Debt/Equity0.17
Current Ratio2.94
Quick Ratio1.82
Book Value/Sh0.89 USD
Cash/Share0.51 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 20, 2019
Splits
Last Split1:10
Split DateDec 20, 2019
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+305.9%
Target Range10.00 USD – 12.00 USD
10.00+305.9% to mean12.00
# Analysts2
Ownership
Shares Out.80.57M
Float77.45M
Insiders3.88%
Institutions18.42%
Short Interest
Short Ratio4.1d
Short % Float3.72%
Short % Out.3.57%
Shares Short2.88M
Short (prev mo.)3.58M
Technical
SMA 502.552 (+6.2%)
SMA 2002.344 (+15.6%)
Beta-0.09
S&P 52W Chg16.45%
Avg Vol (30d)810.39K
Avg Vol (10d)829.63K
Technical Indicators
RSI (14)55.2
MACD0.0536
MACD Signal0.0679
MACD Hist.-0.0144
BB Upper2.813 USD
BB Middle2.716 USD
BB Lower2.618 USD
BB Width7.19%
ATR (14)0.1035 USD
Vol Ratio (20d)0.94x